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The v-abl and v-src oncogenes encode protein-tyrosine kinases that possess different biological properties in
spite of their high degree of amino acid conservation. To correlate functional differences with structural
domains of the two oncogenes, we recombined v-abl and v-src just downstream of the lysines in their
ATP-binding sites, within the kinase domain. The biological activity of the chimeric genes was studied and
compared with that of v-src and v-abl. The v-srclv-abl recombinant shared with v-src and v-abl the ability to
transform fibroblasts. In addition, like v-abl, it transformed lymphoid cells and relieved a hematopoietic cell
line of its interleukin 3 requirement. In contrast, the reciprocal construct, v-abllv-src, was transformation
defective. Lack of biological activity correlated with formation of a stable complex between the chimeric protein
and two cellular proteins and with low kinase activity. We conclude that the specificity within the kinase
domain determines the particular biological behavior of protein-tyrosine kinase oncogenes.
Protein-tyrosine kinases (PTKs) were first identified as
transforming proteins encoded by a class of retroviruses.
These viral proteins represent an altered form of cellular
enzymes strongly conserved throughout evolution (for a
review, see reference 11). Although the biological function
of cellular PTKs remains largely unknown, they are sus-
pected of playing a crucial role in signal transduction path-
ways. One striking feature of these proteins is their high
degree of amino acid sequence homology within the kinase
domain. Despite this sequence conservation, PTKs display
varied biological functions. The functions of growth factor
receptors that have cytoplasmic PTK domains, like those for
epidermal growth factor, insulin, and platelet-derived
growth factor, are obviously different. These functional
differences reflect more than their ligand-binding specificity,
because platelet-derived and epidermal growth factors trig-
ger quite distinct biochemical responses in cells that have
both receptors on their surface (14). That can only be
accomplished if the activated receptor kinases display dif-
ferent substrate specificities. Little is known about what
sequences in these molecules are involved in directing such
specificities, except that they are within the cytoplasmic
region.
To address the question of structure-function relationships
in these proteins and other tyrosine kinases, we chose the
v-abl and v-src oncogenes as models. These oncogenes are
highly related in amino acid sequences (26, 30, 32), but have
distinct biological properties (10, 17, 19, 27, 29). Abelson
murine leukemia virus (A-MuLV) (v-abl) transforms both
fibroblasts and lymphoid cells in vitro (27, 29) and relieves
interleukin 3 (IL-3)-dependent cells of their growth factor
requirement (5, 19, 21, 23). Rous sarcoma virus (v-src)
transforms fibroblasts, but only causes lymphoid transfor-
mation and IL-3 independence poorly if at all (10, 17, 19, 22).
These differences are clearly a function of the oncogenes
proper: placing v-src in a structural configuration resembling
that of v-abl in A-MuLV failed to duplicate the biological
properties of A-MuLV or other viruses carrying the v-abl
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oncogene (17, 19). To identify sequences responsible for
these biological differences and implicitly responsible for
substrate specificity, we recombined v-abl and v-src just
downstream of the lysine in the ATP-binding sites (12),
within the kinase domain. The chimeric genes were charac-
terized biochemically and their biological activity was com-
pared with that of v-abl and v-src.
MATERIALS AND METHODS
Cells, virus, and transfection. Normal and transformed
NIH 3T3 fibroblasts were grown in Dulbecco modified Eagle
medium with 10% calf serum. Bone marrow cells, obtained
from tibias and femurs of 3-week-old BALB/c mice, were
cultured in RPMI medium containing 10% fetal calf serum
and 50 ,uM 3-mercaptoethanol. Ba/F3 cells (19) were grown
in RPMI medium with 10% fetal calf serum and 10% WEHI-3
cell-conditioned medium (as a source of IL-3). V-SRC virus
and Moloney murine leukemia virus (Mo-MuLV) have been
described (17). Titers of the various viruses were determined
by focus assay on NIH 3T3 cells. Infection of bone marrow
cells was performed in liquid cultures as described (27).
Transfections and screening of focus formation were done as
described (17).
Antisera and protein biochemistry. Tumor-bearing rabbit
antiserum (derived against Rous sarcoma virus strain D
proteins) a-VBII and anti-gag protein antiserum have been
described (17). Anti-abl 584 antiserum (33) was a gift from
J. Wang. Anti-src monoclonal antibody MAb327 (15) was a
gift from J. Brugge. Cell extracts, immunoprecipitations,
[35S]methionine labeling, and in vitro kinase reactions were
performed as described (18). When warranted, changes in
these procedures have been indicated in the text. Glycerol
gradients were run by the method of Buss et al. (4). Frac-
tions were collected from the top. Polyacrylamide gel elec-
trophoresis was done by the procedure of Laemmli (13).
Gels (7.5 or 8.5% acrylamide) were run at constant voltage.
Mutagenesis and plasmid construction. The point mutation
in v-src was obtained by site-directed mutagenesis with a
specific oligonucleotide. The 260-base-pair (bp) PstI frag-
ment of v-src, containing the site to be mutated, was sub-
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cloned in M13mp8. The proper orientation of the fragment
was ensured by sequencing. The 19-mer oligonucleotide
5'-CCTCCGGGGCCATGGTGCC-3' was obtained from the
Whitehead Institute oligonucleotide synthesis facility. An-
nealing of the oligonucleotide and M13 universal template
primer to M13 template containing the PstI fragment and
repair-ligation reactions and screening of mutagenized
clones were performed as described (37). The T-to-G trans-
version was confirmed by the creation of a novel NcoI site
within the PstI fragment and independently by sequencing.
pV-SRCneo plasmid. pV-SRC plasmid DNA (17) was cut
with KpnI (unique site in the long terminal repeats [LTRs]).
The v-src-containing fragment was cloned in pUC-ABX2
(see below), similarly cut with KpnI. This intermediate was
then cut with MluI and StuI. These sites are unique in the
PstI fragment of v-src used for mutagenesis and lie on either
side of the planned mutation (30, 32). The M13 clone
containing the mutagenized v-src fragment was also cut with
MluI and StuI; the small v-src fragment (now containing an
NcoI site) was recloned in the doubly digested pUC inter-
mediate (described above) to yield pV-SRCnco plasmid (see
Fig. 2).
pUC-ABX2 plasniid. To create the pUC-ABX2 plasmid
(referred as pABX2 in the text), the ABX2 plasmid (25) was
modified as follows. Rat sequences flanking the 5' and 3'
LTRs of ABX2 provirus were trimmed by digesting with
HincII (partial) and BstEII (complete). The new ends were
converted into an HindIII site (5') and EcoRI site (3'). The
provirus was then subcloned in the polylinker of the pUC13
plasmid (see Fig. 2).
pV-ARC plasmid. pABX2 plasmid DNA was cut with
NcoI and HindIII, and the large fragment was isolated.
pV-SRCnco plasmid DNA was similarly cut with NcoI and
HindIII, and the small v-src-containing fragment was ligated
to the large fragment isolated above (see Fig. 2).
pV-SBL plasmid. pV-SRCnco plasmid DNA was cut with
NcoI and HindIII. The larger fragment containing the 5' half
of v-src was isolated. pABX2 was cut with NcoI and
0
-
- AI KTLK|PGIT Mj
ACC ATC
HindIII, and the smaller fragment was ligated to that isolated
above (see Fig. 2).
RESULTS
To identify the sequences that distinguish the biological
activity of v-abl from that of v-src, we created reciprocal
recombinants between the two genes and studied how the
v-abl phenotype segregated in each recombinant. For this
purpose, a region just downstream of the lysine in the
ATP-binding site of v-abl and v-src was chosen for recom-
bination (Fig. 1). In v-abl, an NcoI site (CCATGG) is
present, whereas the corresponding sequence in v-src (based
on amino acid alignment) is CCATGT. We used oligonucle-
otide-directed mutagenesis to make a T-to-G transversion in
the above v-src hexamer sequence. This created an NcoI site
in v-src and replaced a serine residue with an alanine residue
(Fig. 1). The entire v-src gene, containing the mutated
fragment, was reconstructed and inserted back into a murine
retroviral vector. This construct, pV-SRCnco, was cotrans-
fected with helper virus Mo-MuLV plasmid DNA (pZAP)
into NIH 3T3 cells, and its activity was compared with that
of the wild-type construct, pV-SRC. We observed no differ-
ences in efficiency or time of focus appearance. Further-
more, viral stocks prepared from cells transfected with
pV-SRCnco or pV-SRC showed comparable titers (data not
shown). The transforming protein detected in pV-SRCnc'-
transformed cells displayed a high level of in vitro tyrosine
kinase activity (see Fig. 4, lane a). It also comigrated with
wild-type p60vsrc during electrophoresis through a sodium
dodecyl sulfate (SDS)-polyacrylamide gel (data not shown).
Because pV-SRCnco was biologically active and behaved
identically to pV-SRC, we proceeded with the recombina-
tion outlined in Fig. 2. Parental DNAs, pV-SRCnco, and
pABX2 were recombined at the NcoI site to yield two
reciprocal constructs, pV-SBL (srclabl) and pV-ARC
(abllsrc). These constructs were tested for biological activity
on NIH 3T3 cells. DNAs were cotransfected into these cells
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FIG. 1. Strategy of recombination. Amino acid sequence comparison of v-src and v-abl is shown around the region where mutagenesis was
targeted. Homologous residues are boxed. The NcoI sequence in v-abl (CCATGG) is indicated. The T-to-G transversion in v-src is indicated.
The newly created Ncol site and serine-to-alanine change in V-SRCnc' are diagrammed. The solid circle identifies the lysine residue in the
ATP-binding site. Generation of the recombinants between v-abl and v-srcnco is outlined.
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FIG. 2. Recombinant plasmids. Proviral structures of pV-SRC, pV-SRCnco, pABX2, pV-ARC, and pV-SBL. Major restriction sites used
for the cloning and recombination steps are indicated: Bs, BstEII; E, EcoRI; H, Hindlll; Hc, HincII; N, NcoI; X, Xhol. Shaded boxes,
Mo-MuLV LTRs; open boxes, v-src sequence; hatched boxes, v-abl sequence; thick solid line, A-MuLV-derived gag sequence.
with pZAP DNA (Mo-MuLV helper DNA) and pSV2neo
(which confers G418 resistance [31]) DNAs. Two days later,
cells were split into two sets; one set was selected in the
presence of G418, and the other was checked for the
appearance of foci. Parental DNAs (pV-SRCnco and pABX2)
were transfected by the same protocol. Foci were observed
simultaneously in pV-SRCnco, pABX2, and pV-SBL cul-
tures. We did notice a slight decrease (three- to fivefold) in
the number of foci with pV-SBL compared with pABX2
(data not shown). Surprisingly, we detected no foci in
pV-ARC cultures. When G418-resistant colonies were
scored, we saw equivalent numbers of colonies in pV-
SRCnco and pV-ARC cultures. A dramatic reduction in
number was evident in pABX2 and pV-SBL plates. Whereas
the vast majority of pV-SRCnc, colonies were transformed
(over 90%), none of the pABX2 or pV-SBL G418-resistant
colonies were. This is usually observed with plasmids that
produce A-MuLV and results from a toxic effect of v-abl on
transfected cells (36). Foci seen in unselected cells result
from the spread of infectious virus transiently expressed in
cells cotransfected with v-abl and pZAP plasmid DNAs.
These results indicate that, in fibroblasts, pV-SBL behaves
similarly to pABX2, whereas pV-ARC is transformation
defective. To examine whether pV-ARC might cause tem-
perature-sensitive transformation, we placed the G418-resis-
tant colonies or unselected cultures at 32 or 39°C. This had
no effect on cell morphology in either set of plates, even after
a prolonged incubation of 5 days.
To obtain virus stocks and check for synthesis of the viral
chimeric proteins, we obtained cell clones from each of the
transfected cultures. pV-SRCnco, pABX2, pV-SBL, and
pV-ARC cell clones and uninfected NIH 3T3 cells were then
labeled with [35S]methionine, and cell extracts were made.
Portions were immunoprecipitated with a battery of specific
antisera which recognized gag (a-gag), v-src (aVBII,
MAb327), or v-abl (a-584) determinants. pV-SBL-directed
protein has a predicted molecular mass of 89 kilodaltons
(kDa), consisting of v-src and v-abl sequences. pV-ARC-
encoded protein contains gag, v-abl, and v-src sequences
and has a predicted molecular mass of 68 kDa. When
extracts were immunoprecipitated with a-gag antiserum,
viral gag precursor PrOg'g polyprotein, encoded by helper
virus Mo-MuLV, was detected in all of the transfected
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FIG. 3. Protein characterization. NIH 3T3 cell clones (A, B, C)
or lymphoid cells (D) were labeled with [355]methionine for 4 h.
Equal amounts of trichloroacetic acid (TCA)-precipitable counts
from the labeled cell extracts were immunoprecipitated with various
antisera, and immune complexes were separated by electrophoresis
through an 8.5% polyacrylamide-SDS gel. (A) a-gag antiserum.
Lanes: a, pV-SRCnc' cells; b, pV-ARC cells; c, pABX2 cells; d,
uninfected cells. (B) a-584 a-abl antiserum (lanes a to c) and
MAb327 a-src monoclonal (lanes d to f). Lanes: a, pABX2 cells; b
and d, pV-SBL cells; c and f; uninfected cells; e, pV-SRCnc' cells.
(C) aVBII a-src antiserum. Lanes: a, pV-ARC cells. (D) a-gag
antiserum (lane a) and MAb327 a-src monoclonal (lane b). pV-SBL
cells. Lanes M, Marker lanes; the same set of markers was used in
panels A, B, and D. Open arrowhead points to the protein of interest
in the different lanes. Sizes are indicated to the left of panel A (in
kilodaltons).
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clones (Fig. 3A, lanes a, b, and c). As expected, a protein of
100 kDa, plOOgag-abI, was observed in pABX2-transformed
cells (lane c). In pV-ARC cells, the expected 68-kDa protein
was detected, but three other proteins were also evident
(lane b). The strongly reactive protein of 58 kDa was
recognized by a-gag antiserum but not by a-src antiserum
(Fig. 3C). It may represent some gag intermediate, but its
exact identity is at present unclear. The two other proteins
(better seen in Fig. 5) were 90 and 50 kDa in mass (faint in
this figure). These proteins were also observed when a-VBII
was used (Fig. 3C). In all likelihood, they are the two cellular
proteins, hsp90 and p50, previously described as forming a
specifice &mplex with p6`v'src and some other src-related
proteins (2). Evidence for such a complex with the pV-ARC-
encoded protein, P68"c, is provided below.
The same extracts were reacted with a-abl antiserum (Fig.
3B, lanes a to c) or MAb327 (a-src) (lanes d to f). pljfgag-abI
was readily detected, as well as its glycosylated form (35),
which runs more slowly (lane a; also seen in lane c, Fig. 3A).
In pV-SBL-transformed cells, we observed a protein with
the expected size of 89 kDa (lane b). This protein was also
recognized by MAb327 (lane d), but was not detected with
either antiserutn in uninfected NIH 3T3 cells (lanes c and f).
Theseproperties are in agreement with the expected behav-
ior of the transforming protein encoded by pV-SBL, P89sbI.
Fina1iy, when pV-SRCnco cell extracts were immunoprecip-
itated with MAb327 (lane e), the expected 60-kDa v-src
protein was detected. The 60-kDa protein in lanes d and f
(paiibl B) and in lane b (panel D) represents endogenous
mouse c-src protein.
To test whether the viral chimeric proteins exhibited PTK
activity, extracts from unlabeled cell clones were immuno-
precipitated and immune complexes were assayed for in
vitro kinase activity. Transforming proteins of pV-SRCnco,
pABX2, and pV-SBL were all autophosphorylated in this
assay (Fig. 4). The phosphoprotein migrating at about 125
kDa in lane a was consistently detected in association with
p6 v-src when MAb327 was used for immunoprecipitation.
Although probably a cellular protein, its nature has not been
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FIG. 4. In vitro kinase activity. Cell extracts containing equal
amount of protein were immunoprecipitated with a-gag (lane b) or
MAb327 a-src (lanes a and c). Immune complexes were washed and
suspended in kinase buffer and incubated for 20 min at 25°C. The
reaction was stopped by adding Laemmli sample buffer (13). Sam-
ples were electrophoresed through an 8.5% polyacrylamide-SDS
gel, and phosphoproteins were visualized after autoradiography of
the dried gel. Lanes: a, pV-SRCnco NIH 3T3; b, pABX2 NIH 3T3;
c, pV-SBL NIH 3T3. M, Standards (in kilodaltons) and the trans-
forming proteins are indicated.
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FIG. 5. Quantitation of kinase-specitic activity. NIH 3T3 cells
(7.5 x 10-'), infected with V-ARC or ABX2 virus, were labeled with
400 ,uCi of ["Simethionine. Incorporation in the protein extracts
were monitored by TCA precipitation and counting. Portions of
each lysate containing equal amounts of TCA-precipitable counts
were immunoprecipitated with excess anti-gag antiserum. The
immune complexes were either directly separated on a 10o poly-
acrylamide-SDS gel (A) or incubated as described in the legend to
Fig. 4 in kinase buffer containing a-casein (0.3 mg/ml) prior to
electrophoresis (B). Lanes: a, ABX2 NIH 3T3 cells; b, V-ARC NIH
3T3 cells. Phosphoproteins in panel B were visualized after autora-
diography of a dried gel that had been covered with two layers of
aluminum foil to block the c(fttribution of [15S]methionine radiation
emitted by P68Grc and p1j)gag-abl. The a-casein band was excised
from the gel, and 32P incorporation was quantitated in scintillation
fluid. *, 58-kDa "gag"-related protein.
investigated further. For the pV-ARC extracts, very little
radioactivity was detected in association with P68arc (data
not shown).
The apparently very low kinase activity of P68"' could
explain the failure of V-ARC virus to transform fibroblasts.
To investigate its activity more precisely, V-ARC- and
ABX2-infected fibroblasts were labeled for 18 h with [355]
methionine, and levels of P68"' and pjOOgag-abl were ana-
lyzed after immunoprecipitation with anti-gag antiserum
(Fig. 5A). Because we detected similar amounts of both
proteins after this long labeling period, we could exclude the
possibility that P68"tC expression was too low to achieve
transformation of fibroblasts. When plWfgag-abl and P68a',
immunoprecipitated from identical portions of the lysates
shown in Fig. 5A, were compared for their ability to phos-
phorylate in vitro the exogenous substrate a-casein, P68arc
showed 23-fold lower activity (Fig. 5B). A 26-fold lower
activity was measured when enolase was used as a substrate
(data not shown). Thus, the defectiveness of V-ARC virus is
best explained by the low specific PTK activity of P68arc.
As noticed previously, P68arc was recovered in associa-
tion with two cellular proteins presumed to be hsp90 and
p50. To determine what proportion of P68"c was in such a
complex, pV-ARC cells were labeled with [35S]methionine
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FIG. 6. Demonstration of P68"rC in a complex. pV-ARC
NIH/3T3 cells were labeled with [35S]methionine for 14 h. Cells were
lysed and clarified (4). The lysate was overlaid on a 5 to 20%o glycerol
gradient and centrifuged for 19 h at 40,000 rpm (150,000 x g) at 4°C
in a Beckman SW50.1 rotor. Gradient fractions (0.2 ml) were
collected from the top. The two labeled proteins in fractions 3 to 11
represent Pr659'9 and a gag-related 58-kDa protein. The two cellular
proteins and P68arc are indicated.
for 14 h, and a clarified lysate was centrifuged through a
glycerol gradient. Fractions were collected and analyzed by
SDS-polyacrylamide gel electrophoresis after immunopre-
cipitation with a-gag antiserum (Fig. 6). The free form of
P68arC would be found in the same fractions as Pr659ga and
the "gag-related" 58-kDa proteins which migrate as mono-
mers. It is clear from this analysis, however, that P68atC
protein did not sediment as a monomer; rather, the majority
sedimented as a much larger species and cosedimented with
50- and 90-kDa proteins. Thus, nearly all of P68a was
bound up in a complex with the two cellular proteins hsp90
and p50. Interestingly, we were unable to detect plgag-abl,
even transiently, in a similar complex (data not shown).
As a final biochemical characterization of the chimeric
proteins, we examined their divalent cation requirement in
the in vitro kinase reaction. Immune complexes containing
the pV-SRC, pV-SRCnco, pABX2, or pV-SBL transforming
protein were suspended in kinase buffer containing either 10
mM Mg2+, 10 mM Mn2+, or no divalent cations. Very little
activity was detected (less than 1%) for all proteins in the
absence of divalent cations (data not shown). p6V-src en-
coded by pV-SRC, demonstrated a slight preference for
Mn2+ over Mg2+ in this assay (Table 1). Surprisingly,
p60v-src encoded by pV-SRCnco showed a marked preference
for Mn2+. This difference is probably a consequence of the
fact that the mutation introduced in pV-SRCnco is so close to
the ATP-binding site (Fig. 1). Likewise, P89sb1 showed
higher activity when Mn2+ was present in the assay.
plOOgag-abl also preferred Mn2+, but the difference was not
as marked (Table 1).
To examine the effects of the various viruses on lymphoid
and Ba/F3 cells (Table 2), we obtained virus stocks from the
various cell clones. V-SRCnco, ABX2, and V-SBL viruses
were all transforming, having titers from 5 x 105 to 106
focus-forming units per ml (data not shown). V-ARC virus,
TABLE 1. Cation preference of viral kinasesa
o% of maximal activity
Virus Protein
Mg2+ Mn2+
ABX2 P100 49 100
V-SRC p60 80 100
V-SRCnco p60 16 100
V-SBL P89 11 100
a Immunoprecipitates containing the indicated proteins were assayed for
PTK activity in vitro. Samples were suspended in kinase buffer (50 mM
HEPES [pH 7.41, 10 mM Mg(CH3CO2)2 or MnCl2, 0.7 FM [y-32P]ATP, 5%
glycerol) and incubated for 20 min at 25°C. After autoradiography, gel bands
containing the phosphoproteins were excised and counted. Results are given
as percentage of maximal activity obtained. pj()Ogg-abl was immunoprecipi-
tated with a-gag antiserum; p60`src (of V-SRC or V-SRCIc) and pg9sbl were
immunoprecipitated with MAb327.
as expected, was transformation defective on fibroblasts, but
the V-ARC genome was passed at good efficiency, as mea-
sured by expression of the predicted protein in freshly
infected cells (data not shown).
To study the effect of these viruses on bone marrow cell
transformation, cells collected from the femurs and tibias of
3-week-old mice were infected in liquid cultures with each
viral stock, as well as with Mo-MuLV and V-SRC viruses.
V-ARC and Mo-MuLV viruses had no effect on the bone
marrow cultures. V-SRC and V-SRCnco viruses caused a
transient burst of proliferation in the infected cultures. We
were unable, however, to recover any transformed cells,
even 3 months after infection and cultivation of the cells over
a bone marrow-derived feeder layer. ABX2 and V-SBL
viruses, by contrast, elicited continuous proliferation of
suspension cells at equal efficiency. Transformed cells were
established in the absence of feeder cells 3 weeks after
infection. We confirmed that cells transformed with V-SBL
virus synthesized P89sbl protein (Fig. 3D, lane b). We also
found that these cells had rearranged their immunoglobulin
genes in a configuration typical of pre-B cells (8) (data not
shown). Thus, in this assay, V-SBL virus behaved identi-
cally to ABX2 virus.
The above viruses were next used to infect Ba/F3 cells.
These cells are early lymphoid precursor cells that require
IL-3 for growth in vitro. v-abl transformation confers IL-3
independence on Ba/F3 cells, whereas v-src transformation
TABLE 2. Biological properties of parental and chimeric viruses
Fibroblast Lymphoid IL-3 inde-
Virus Protein Oncogene transfor- transfor- pendence6
mation mationa
ABX2 P100 abl Yes Yes Yes
V-SRC p60 src Yes No Partialc
V-SRCnco p60 src Yes No Partialcd
V-ARC P68 abl/src No No No
V-SBL P89 srclabl Yes Yes Yes
a 106 bone marrow cells were infected with 1 ml of virus in liquid culture
(26). Cells were monitored for 3 months. Suspension cells were taken
periodically off the bone marrow-derived feeder layer and tested for their
ability to become established. V-SBL and ABX2 cultures were established 3
weeks after infection.
b 106 Ba/F3 cells were infected with 1 ml of virus as described (19).
Proliferation of cells was monitored 4 days after the infected cells were placed
in medium without IL-3, and continuous growth was monitored over the next
week.
c IL-3 was necessary for continuous growth, but the requirement was
reduced compared with uninfected cells.
d Lower amounts of IL-3 were required for growth compared with V-SRC
cultures.
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only lowers the IL-3 requirement of these cells (19). Two
days after infection with the various stocks, Ba/F3 cells were
placed in medium lacking IL-3. Proliferation of the mass
cultures was assessed 4 days later. At that time, no surviving
cells could be observed in Mo-MuLV and V-ARC cultures.
In contrast, cells infected with ABX2 or V-SBL viruses were
actively proliferating and looked very healthy. In both cases,
cells became totally IL-3 independent. Again, we were
unable to distinguish the biological effect of V-SBL and
ABX2 viruses.
Cells infected with V-SRCnco virus behaved less well than
the latter cultures, but some proliferation was observed.
After several days in culture, the cell appearance worsened
and significant cell death was observed. These effects were
readily reversed by addition of a small amount of IL-3. The
same situation occurred with V-SRC virus, although the
cells did not do nearly as well as with V-SRCnco virus. The
slight difference in behavior between the two viruses was not
studied further. The results of the various assays with the
viruses are summarized in Table 2.
DISCUSSION
v-abl and v-src oncogenes, despite their high amino acid
sequence homology, elicit different biological effects. This is
best illustrated by lymphoid transformation and abrogation
of IL-3 requirement in cell lines dependent on it for growth
in vitro. Both effects are mediated by v-abl, but neither is
mediated by v-src (17, 19). However, both oncogenes are
very efficient at transforming fibroblasts (10, 17, 29). To
better understand and compare these differences, we have
produced viruses carrying chimeric v-alblv-src or v-srclv-abl
genes. For lack of precise structural knowledge to direct the
site of recombination, we selected an approach that allowed
easy and precise recombination. This led us to create a
restriction site in v-src at a position homologous to a site
already present in v-abl. It required a single nucleotide
replacement in a hexamer sequence just downstream of the
lysine of the ATP-binding site in p6f-vsrc (12). The single
amino acid change (serine to alanine) did not affect the
biological activity of v-src. It did, however, modify the
divalent cation usage of the mutant p60-src in the in vitro
kinase reaction.
The concept of a kinase domain within the PTK genes and
proteins derives from two sources: the high sequence ho-
mology displayed among the PTKs within a subregion of
their individual sequences, and the direct demonstration of
kinase activity in a 30-kDa subfragment of v-src (1, 7; our
observation). One landmark near the N-terminal end of the
kinase domain is the lysine that interacts with ATP (12). By
recombining v-src and v-abl downstream of this lysine, we
ensured that V-ARC received the majority of its kinase from
v-src and V-SBL received the equivalent region from v-abl.
They received about 40 and 30 kDa, respectively, of the
N-terminal amino acid sequence from the other partner. This
sequence contains regions of v-srclv-abl homology but is
much less homologous than the kinase region and might have
been thought to encode the transformation specificity.
The virus carrying the v-srclv-abl oncogene, V-SBL,
behaved biologically like ABX2 virus (or A-MuLV). It
transformed fibroblasts and lymphoid cells in vitro and
rendered Ba/F3 cells IL-3 independent. The efficiency of
V-SBL and ABX2 viruses in eliciting these effects was
similar, but a small decrease in focus formation after trans-
fection of pV-SBL DNA was noted.
Thus, the v-abl sequence present in V-SBL virus appears
to induce effects usually ascribed to the entire v-abl se-
quence. Unfortunately, the behavior of V-ARC virus was
not reciprocal to that of V-SBL; rather, V-ARC virus was
transformation defective. This lack of transformation corre-
lated with two biochemical findings. V-ARC protein had
very low specific kinase activity, and the majority of the
protein was recovered as a complex with two cellular
proteins, hsp9O and p50 (2). The reason for the complex
formation is not known. Perhaps the two cellular proteins
recognize in P68arc an unproperly folded molecule and
sequester it, in a complex, away from the plasma membrane.
Alternatively, P68arc protein may lack sequences normally
involved in releasing p60v-src from the complex with p50 and
hsp90. We tested this possibility by replacing the gag
sequences of P68arc with the first 110 amino acids of p60vsrc.
The gag and N-terminal src sequences had been shown
previously to be interchangeable in chimeric constructs (17).
This replacement, however, failed in releasing the new
chimeric protein from its complex. It also resulted in a
transformation-defective protein with low kinase activity
(data not shown). Also unresolved is the reason for the low
kinase activity of P68"rc. It could be either an intrinsic
enzymatic defect or the consequence of sequestration of the
protein in a complex. Previously, it had been reported that
the kinase activity of p6vsrc complexed to p50 and hsp90 is
significantly reduced (3, 6), but this view has recently been
challenged (9).
Regardless of these open questions, our results demon-
strate two significant points. Despite the lack of relevant
information about the three-dimensional structure of p60v-src
or plOOgag-abl to suggest a recombination site, we did suc-
ceed in creating a functional chimeric protein. One of the
products of the v-srclv-abl recombination, P89sbl, was both
enzymatically and biologically active. This success under-
scores the relatedness of v-src and v-abl.
These experiments show that induction of IL-3 indepen-
dence and transformation of lymphoid cells both correlate
with the sequences common between V-SBL and ABX2
viruses, mainly the PTK domain. The fact that V-ARC virus
is transformation defective is noninformative in this respect.
Recently, Privalsky (24) fused the first 119 N-terminal amino
acids of v-erbB to amino acids 226 to 526 of v-src. The
chimeric gene induced fibroblast transformation and ex-
pressed a hybrid protein with biochemical characteristics
similar to those of v-src (24). The chimera failed, however, in
transforming erythroid cells. Thus, target cell specificity of
v-src was not influenced by the v-erbB sequence present in
the hybrid. Erythroid transformation therefore appears to
require v-erbB sequences encoded in the kinase domain of
this oncogene.
The common sequences between V-SBL and ABX2 vi-
ruses do extend downstream of the v-src homology in v-abl.
These additional sequences are not in the kinase domain
proper and might also contribute to the biological properties
of these viruses. In fact, the region downstream of the kinase
domain of v-abl in A-MuLV has been linked in vitro to
enhanced lymphoid transforming ability by this virus and in
vivo to enhanced tumorigenicity (28). This finding does not,
however, indicate that sequences beyond the PTK domain are
necessary for lymphoid transformation, because certain var-
iants of an A-MuLV strain which lack most of these 3'
sequences, although crippled in their ability to transform
lymphoid cells in vitro, can induce lymphomas in vivo with an
efficiency comparable to that of wild-type A-MuLV (20).
Even though important interactions are likely to be mediated
by this sequence, the region appears to serve as a modulator
of the intrinsic biological properties of the v-abl kinase
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domain. The existence of complex interactions within the
v-abl sequences should not obscure the main conclusion of
these experiments: the transformation specificity of a viral
PTK has been localized to a region that is coincident with the
center of catalytic activity, implying that it is probably cata-
lytic specificity which determines transformation specificity.
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